Theranexus Société Anonyme (ALTHX.PA)

EUR 0.64

(32.37%)

Market Cap (In EUR)

4.9 Million

Revenue (In EUR)

296.33 Thousand

Net Income (In EUR)

-6.82 Million

Avg. Volume

11.3 Thousand

Currency
EUR
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.46-1.348
PE
-
EPS
-
Beta Value
2.355
ISIN
FR0013286259
CUSIP
F93350100
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Mathieu Charvériat
Employee Count
-
Website
https://www.theranexus.com
Ipo Date
2017-10-30
Details
Theranexus société anonyme, a biopharmaceutical company, develops drug candidates for the treatment of central nervous system disorders. The company's lead drug candidate is THN102, which is in Phase II clinical trial to treat sleep/wake disorders. It also develops THN201 for the treatment of neurocognitive disorders linked to Alzheimer's disease; and THN101 to treat neuropathic pain. The company was founded in 2013 and is based in Lyon, France.